Literature DB >> 11401008

Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.

H Murck1, R M Frieboes, I A Antonijevic, A Steiger.   

Abstract

RATIONALE: EMD 68843 (EMD) has properties of a serotonin (5-HT)-reuptake inhibitor and a partial 5-HT1A agonist in one molecule in order to combine antidepressive and anxiolytic properties.
OBJECTIVE: We investigated the effects of EMD on the sleep EEG in order to characterize how the complex interaction between these two properties influences the sleep EEG.
METHODS: We performed a randomized crossover study in ten young normal male controls (20-30 years), receiving a single dose of 20 mg EMD or placebo orally at 2100 hours. Sleep EEG was recorded from 2300 to 0700 hours.
RESULTS: After EMD, rapid eye movement (REM) sleep was nearly totally abolished. In the course of the night other effects on the sleep EEG occurred in distinct intervals. Slow wave sleep and EEG delta power increased in the first and third one-third of the night, whereas wakefulness was enhanced in the second and third one-third of the night.
CONCLUSION: The sleep EEG effects of EMD fit with its pharmacological profile, which might lead to adaptive changes suggested to characterize an antidepressive substance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401008     DOI: 10.1007/s002130100703

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review.

Authors:  Michael E Thase; Harald Murck; Anke Post
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.

Authors:  Heike E Kuenzel; Axel Steiger; Katja Held; Irina A Antonijevic; Ralf-Michael Frieboes; Harald Murck
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 3.  Vilazodone: in major depressive disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 4.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

5.  Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.

Authors:  Thomas L Schwartz; Umar A Siddiqui; Stephen M Stahl
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

6.  Translatability scoring in drug development: eight case studies.

Authors:  Alexandra Wendler; Martin Wehling
Journal:  J Transl Med       Date:  2012-03-07       Impact factor: 5.531

7.  Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use.

Authors:  Mandeep Singh; Thomas L Schwartz
Journal:  Neuropsychiatr Dis Treat       Date:  2012-03-23       Impact factor: 2.570

Review 8.  Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action.

Authors:  Sheng-Min Wang; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae
Journal:  Psychiatry Investig       Date:  2015-03-18       Impact factor: 2.505

Review 9.  Vilazodone for the Treatment of Depression: An Update.

Authors:  Sheng-Min Wang; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae
Journal:  Chonnam Med J       Date:  2016-05-20

Review 10.  The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression.

Authors:  Yi-Qun Wang; Rui Li; Meng-Qi Zhang; Ze Zhang; Wei-Min Qu; Zhi-Li Huang
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.